Concepts (263)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 44 | 2023 | 682 | 4.230 |
Why?
|
| Anti-HIV Agents | 23 | 2023 | 152 | 2.950 |
Why?
|
| HIV-1 | 14 | 2015 | 72 | 1.910 |
Why?
|
| Pyridazines | 5 | 2010 | 6 | 0.990 |
Why?
|
| CD4 Lymphocyte Count | 20 | 2022 | 176 | 0.950 |
Why?
|
| Viral Load | 16 | 2018 | 132 | 0.940 |
Why?
|
| Antiviral Agents | 7 | 2020 | 96 | 0.920 |
Why?
|
| Reverse Transcriptase Inhibitors | 7 | 2013 | 21 | 0.880 |
Why?
|
| Adult | 49 | 2023 | 7696 | 0.830 |
Why?
|
| Antiretroviral Therapy, Highly Active | 11 | 2017 | 96 | 0.780 |
Why?
|
| Hepatitis C, Chronic | 7 | 2015 | 65 | 0.760 |
Why?
|
| Male | 49 | 2023 | 10173 | 0.700 |
Why?
|
| Humans | 62 | 2023 | 18058 | 0.680 |
Why?
|
| Middle Aged | 40 | 2023 | 8073 | 0.650 |
Why?
|
| Female | 48 | 2023 | 12838 | 0.630 |
Why?
|
| Electronics, Medical | 1 | 2018 | 3 | 0.630 |
Why?
|
| Hepacivirus | 7 | 2015 | 51 | 0.610 |
Why?
|
| Carbamates | 6 | 2015 | 7 | 0.600 |
Why?
|
| Sofosbuvir | 5 | 2015 | 5 | 0.580 |
Why?
|
| Acquired Immunodeficiency Syndrome | 3 | 2017 | 66 | 0.570 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 4 | 2015 | 4 | 0.540 |
Why?
|
| Cohort Studies | 21 | 2023 | 2631 | 0.520 |
Why?
|
| Treatment Outcome | 19 | 2020 | 1259 | 0.510 |
Why?
|
| Hepatitis B | 3 | 2022 | 43 | 0.500 |
Why?
|
| California | 19 | 2018 | 2327 | 0.480 |
Why?
|
| Pyrrolidinones | 3 | 2014 | 4 | 0.470 |
Why?
|
| Hepatitis B Vaccines | 4 | 2023 | 46 | 0.470 |
Why?
|
| Liver Diseases | 1 | 2012 | 25 | 0.420 |
Why?
|
| Anti-Retroviral Agents | 6 | 2015 | 80 | 0.420 |
Why?
|
| Electronic Health Records | 1 | 2018 | 734 | 0.410 |
Why?
|
| Young Adult | 15 | 2018 | 2479 | 0.400 |
Why?
|
| HIV Envelope Protein gp41 | 3 | 2010 | 4 | 0.390 |
Why?
|
| Peptide Fragments | 3 | 2010 | 28 | 0.390 |
Why?
|
| Myocardial Infarction | 3 | 2022 | 251 | 0.390 |
Why?
|
| Raltegravir Potassium | 4 | 2018 | 9 | 0.380 |
Why?
|
| Drug Resistance, Viral | 7 | 2015 | 13 | 0.360 |
Why?
|
| Aged | 21 | 2020 | 6258 | 0.340 |
Why?
|
| Life Expectancy | 2 | 2020 | 33 | 0.320 |
Why?
|
| Neoplasms | 4 | 2015 | 464 | 0.300 |
Why?
|
| Exercise Therapy | 2 | 2019 | 70 | 0.290 |
Why?
|
| Prenatal Care | 1 | 2008 | 136 | 0.290 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2008 | 139 | 0.280 |
Why?
|
| RNA, Viral | 8 | 2015 | 62 | 0.280 |
Why?
|
| Ritonavir | 4 | 2010 | 7 | 0.280 |
Why?
|
| Hospitalization | 4 | 2023 | 813 | 0.280 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 163 | 0.260 |
Why?
|
| HIV | 2 | 2017 | 26 | 0.260 |
Why?
|
| Sulfonamides | 4 | 2014 | 15 | 0.260 |
Why?
|
| Dideoxynucleosides | 3 | 2016 | 8 | 0.250 |
Why?
|
| Emergency Service, Hospital | 2 | 2019 | 357 | 0.240 |
Why?
|
| Vaccination | 3 | 2020 | 664 | 0.240 |
Why?
|
| Risk Factors | 11 | 2016 | 3394 | 0.230 |
Why?
|
| Anaphylaxis | 1 | 2023 | 15 | 0.230 |
Why?
|
| Adolescent | 8 | 2018 | 3714 | 0.230 |
Why?
|
| Thrombosis | 1 | 2023 | 11 | 0.230 |
Why?
|
| Drug Therapy, Combination | 8 | 2015 | 118 | 0.220 |
Why?
|
| Fractures, Bone | 1 | 2023 | 91 | 0.220 |
Why?
|
| Genotype | 7 | 2015 | 251 | 0.220 |
Why?
|
| Lymphoma, AIDS-Related | 3 | 2011 | 18 | 0.220 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2023 | 62 | 0.210 |
Why?
|
| Risk | 3 | 2020 | 552 | 0.210 |
Why?
|
| Incidence | 7 | 2016 | 1297 | 0.210 |
Why?
|
| Mutation | 3 | 2012 | 129 | 0.210 |
Why?
|
| Herpes Zoster | 1 | 2023 | 86 | 0.200 |
Why?
|
| HIV Protease Inhibitors | 3 | 2010 | 13 | 0.200 |
Why?
|
| Case-Control Studies | 5 | 2020 | 1164 | 0.200 |
Why?
|
| Patient Compliance | 4 | 2014 | 303 | 0.200 |
Why?
|
| HIV Reverse Transcriptase | 2 | 2012 | 2 | 0.190 |
Why?
|
| Pre-Exposure Prophylaxis | 1 | 2021 | 18 | 0.190 |
Why?
|
| Treatment Adherence and Compliance | 1 | 2020 | 13 | 0.190 |
Why?
|
| Oligopeptides | 3 | 2010 | 6 | 0.190 |
Why?
|
| Pyridines | 3 | 2010 | 10 | 0.190 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 4 | 0.190 |
Why?
|
| Alanine | 1 | 2020 | 6 | 0.190 |
Why?
|
| HIV Protease | 2 | 2010 | 4 | 0.180 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 50 | 0.170 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 57 | 0.170 |
Why?
|
| Mentoring | 1 | 2019 | 28 | 0.170 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2018 | 552 | 0.170 |
Why?
|
| Walking | 2 | 2019 | 87 | 0.170 |
Why?
|
| African Continental Ancestry Group | 2 | 2016 | 165 | 0.170 |
Why?
|
| Retrospective Studies | 7 | 2023 | 2498 | 0.160 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 1956 | 0.160 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2018 | 113 | 0.150 |
Why?
|
| Tablets | 1 | 2017 | 2 | 0.150 |
Why?
|
| Common Variable Immunodeficiency | 1 | 2017 | 5 | 0.150 |
Why?
|
| Psoriasis | 1 | 2017 | 9 | 0.150 |
Why?
|
| Organophosphonates | 3 | 2014 | 7 | 0.150 |
Why?
|
| Adenine | 3 | 2014 | 8 | 0.150 |
Why?
|
| Heart Failure | 1 | 2022 | 391 | 0.150 |
Why?
|
| Pneumonia | 1 | 2017 | 54 | 0.140 |
Why?
|
| Darunavir | 3 | 2010 | 4 | 0.140 |
Why?
|
| Pneumococcal Infections | 1 | 2016 | 54 | 0.140 |
Why?
|
| Tenofovir | 4 | 2023 | 18 | 0.140 |
Why?
|
| Pneumococcal Vaccines | 1 | 2016 | 80 | 0.140 |
Why?
|
| Quality of Life | 2 | 2019 | 509 | 0.140 |
Why?
|
| Multivariate Analysis | 3 | 2012 | 595 | 0.130 |
Why?
|
| Uridine Monophosphate | 1 | 2015 | 1 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2015 | 6 | 0.130 |
Why?
|
| Fluorenes | 1 | 2015 | 5 | 0.130 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 97 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2022 | 1294 | 0.130 |
Why?
|
| Coinfection | 1 | 2015 | 30 | 0.130 |
Why?
|
| Isoquinolines | 1 | 2014 | 1 | 0.120 |
Why?
|
| Imidazoles | 1 | 2014 | 4 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2011 | 25 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 113 | 0.120 |
Why?
|
| Hepatitis C | 1 | 2015 | 66 | 0.120 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 77 | 0.120 |
Why?
|
| RNA-Directed DNA Polymerase | 1 | 2013 | 3 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2016 | 316 | 0.110 |
Why?
|
| United States | 5 | 2020 | 4119 | 0.110 |
Why?
|
| Continental Population Groups | 1 | 2015 | 317 | 0.110 |
Why?
|
| Lung Neoplasms | 1 | 2017 | 257 | 0.110 |
Why?
|
| Glomerular Filtration Rate | 2 | 2014 | 156 | 0.110 |
Why?
|
| Healthcare Disparities | 1 | 2015 | 205 | 0.110 |
Why?
|
| Registries | 3 | 2012 | 486 | 0.110 |
Why?
|
| Protease Inhibitors | 1 | 2012 | 5 | 0.110 |
Why?
|
| Patient-Centered Care | 1 | 2015 | 228 | 0.110 |
Why?
|
| Hepatitis B, Chronic | 1 | 2012 | 27 | 0.110 |
Why?
|
| Viremia | 1 | 2012 | 9 | 0.110 |
Why?
|
| Drug Resistance, Multiple, Viral | 1 | 2012 | 6 | 0.100 |
Why?
|
| Primary Health Care | 2 | 2021 | 843 | 0.100 |
Why?
|
| HIV Seropositivity | 1 | 2012 | 31 | 0.100 |
Why?
|
| Health Maintenance Organizations | 3 | 2008 | 481 | 0.100 |
Why?
|
| Managed Care Programs | 1 | 2014 | 356 | 0.100 |
Why?
|
| Liver Cirrhosis | 3 | 2015 | 34 | 0.100 |
Why?
|
| Stroke | 1 | 2014 | 306 | 0.100 |
Why?
|
| Regression Analysis | 1 | 2012 | 319 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2014 | 299 | 0.100 |
Why?
|
| Home Care Services | 1 | 2011 | 23 | 0.100 |
Why?
|
| Drug Combinations | 3 | 2015 | 43 | 0.100 |
Why?
|
| Needs Assessment | 1 | 2011 | 73 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 112 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2016 | 613 | 0.090 |
Why?
|
| Fanconi Syndrome | 1 | 2010 | 4 | 0.090 |
Why?
|
| Social Support | 3 | 2019 | 211 | 0.090 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2015 | 17 | 0.090 |
Why?
|
| Ethnic Groups | 2 | 2015 | 504 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 129 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2011 | 188 | 0.090 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2011 | 177 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 1255 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 3 | 2017 | 118 | 0.080 |
Why?
|
| AIDS Serodiagnosis | 1 | 2008 | 10 | 0.080 |
Why?
|
| Birth Certificates | 1 | 2008 | 22 | 0.080 |
Why?
|
| Lamivudine | 1 | 2008 | 1 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2010 | 328 | 0.080 |
Why?
|
| Alcoholism | 1 | 2012 | 346 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2012 | 445 | 0.080 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2008 | 75 | 0.080 |
Why?
|
| Substance-Related Disorders | 1 | 2012 | 439 | 0.070 |
Why?
|
| Hispanic Americans | 2 | 2015 | 431 | 0.070 |
Why?
|
| Guideline Adherence | 1 | 2008 | 160 | 0.070 |
Why?
|
| Double-Blind Method | 3 | 2015 | 160 | 0.070 |
Why?
|
| Disease Progression | 2 | 2019 | 255 | 0.070 |
Why?
|
| Viral Nonstructural Proteins | 2 | 2015 | 3 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2008 | 233 | 0.070 |
Why?
|
| Atazanavir Sulfate | 3 | 2010 | 5 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 618 | 0.060 |
Why?
|
| Rivaroxaban | 1 | 2023 | 7 | 0.060 |
Why?
|
| Hemorrhage | 1 | 2023 | 63 | 0.060 |
Why?
|
| Mexican Americans | 1 | 2003 | 48 | 0.060 |
Why?
|
| Herpesvirus 3, Human | 1 | 2023 | 47 | 0.060 |
Why?
|
| Pregnancy | 1 | 2008 | 1484 | 0.060 |
Why?
|
| RNA | 1 | 2022 | 12 | 0.050 |
Why?
|
| Outpatients | 1 | 2023 | 113 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2006 | 397 | 0.050 |
Why?
|
| Anticoagulants | 1 | 2023 | 122 | 0.050 |
Why?
|
| Creatinine | 2 | 2014 | 67 | 0.050 |
Why?
|
| Least-Squares Analysis | 2 | 2012 | 16 | 0.050 |
Why?
|
| Child | 1 | 2008 | 2519 | 0.050 |
Why?
|
| Anus Neoplasms | 2 | 2012 | 26 | 0.050 |
Why?
|
| Medication Adherence | 2 | 2015 | 255 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2017 | 1137 | 0.050 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 49 | 0.050 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 10 | 0.050 |
Why?
|
| Immunization Programs | 1 | 2020 | 68 | 0.050 |
Why?
|
| Age Factors | 2 | 2014 | 945 | 0.050 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 86 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 36 | 0.040 |
Why?
|
| Immunization Schedule | 1 | 2020 | 132 | 0.040 |
Why?
|
| Insurance, Health | 1 | 2020 | 221 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 293 | 0.040 |
Why?
|
| Self Report | 1 | 2019 | 252 | 0.040 |
Why?
|
| Los Angeles | 2 | 2011 | 140 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 462 | 0.040 |
Why?
|
| Serogroup | 1 | 2016 | 10 | 0.040 |
Why?
|
| Streptococcus pneumoniae | 1 | 2016 | 25 | 0.040 |
Why?
|
| Vaccines, Conjugate | 1 | 2016 | 66 | 0.040 |
Why?
|
| Risk Reduction Behavior | 1 | 2016 | 114 | 0.030 |
Why?
|
| Ribavirin | 1 | 2015 | 9 | 0.030 |
Why?
|
| Spirometry | 1 | 2015 | 32 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2015 | 75 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 192 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 186 | 0.030 |
Why?
|
| Mass Screening | 1 | 2021 | 678 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 257 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 127 | 0.030 |
Why?
|
| Motivation | 1 | 2015 | 133 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 225 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 17 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2014 | 81 | 0.030 |
Why?
|
| Emtricitabine | 1 | 2014 | 1 | 0.030 |
Why?
|
| Cobicistat | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 2014 | 6 | 0.030 |
Why?
|
| Quinolones | 1 | 2014 | 4 | 0.030 |
Why?
|
| Serologic Tests | 1 | 2014 | 6 | 0.030 |
Why?
|
| Thiazoles | 1 | 2014 | 9 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 7 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2014 | 12 | 0.030 |
Why?
|
| Hepatitis B virus | 1 | 2014 | 21 | 0.030 |
Why?
|
| Gonorrhea | 1 | 2014 | 17 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 2014 | 25 | 0.030 |
Why?
|
| Syphilis | 1 | 2014 | 17 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 215 | 0.030 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2013 | 8 | 0.030 |
Why?
|
| Motor Activity | 1 | 2015 | 208 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 26 | 0.030 |
Why?
|
| Aging | 1 | 2014 | 159 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 705 | 0.030 |
Why?
|
| European Continental Ancestry Group | 1 | 2015 | 559 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 745 | 0.030 |
Why?
|
| SEER Program | 1 | 2012 | 100 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2012 | 36 | 0.030 |
Why?
|
| Nucleosides | 1 | 2012 | 1 | 0.030 |
Why?
|
| Zidovudine | 1 | 2012 | 1 | 0.030 |
Why?
|
| Thymidine | 1 | 2012 | 2 | 0.030 |
Why?
|
| Virus Replication | 1 | 2011 | 12 | 0.030 |
Why?
|
| Sex Factors | 1 | 2014 | 634 | 0.030 |
Why?
|
| Genomics | 1 | 2012 | 65 | 0.030 |
Why?
|
| Phenotype | 1 | 2012 | 145 | 0.030 |
Why?
|
| Patient Advocacy | 1 | 2011 | 12 | 0.030 |
Why?
|
| Insurance Benefits | 1 | 2011 | 15 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 961 | 0.020 |
Why?
|
| Pyrimidinones | 1 | 2010 | 1 | 0.020 |
Why?
|
| Pyrones | 1 | 2010 | 1 | 0.020 |
Why?
|
| Saquinavir | 1 | 2010 | 1 | 0.020 |
Why?
|
| Indinavir | 1 | 2010 | 1 | 0.020 |
Why?
|
| Lopinavir | 1 | 2010 | 1 | 0.020 |
Why?
|
| Organophosphates | 1 | 2010 | 5 | 0.020 |
Why?
|
| Nelfinavir | 1 | 2010 | 4 | 0.020 |
Why?
|
| African Americans | 1 | 2014 | 485 | 0.020 |
Why?
|
| Exanthema | 1 | 2010 | 8 | 0.020 |
Why?
|
| Withholding Treatment | 1 | 2010 | 26 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 235 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 78 | 0.020 |
Why?
|
| Program Evaluation | 1 | 2011 | 236 | 0.020 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 22 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 55 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 667 | 0.020 |
Why?
|
| Prognosis | 1 | 2010 | 619 | 0.020 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2007 | 1 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2008 | 235 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 1114 | 0.020 |
Why?
|
| Medical Indigency | 1 | 2006 | 5 | 0.020 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2006 | 97 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2008 | 692 | 0.020 |
Why?
|
| Logistic Models | 1 | 2008 | 953 | 0.020 |
Why?
|
| AIDS Dementia Complex | 1 | 2003 | 1 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2003 | 5 | 0.010 |
Why?
|
| Mexico | 1 | 2003 | 21 | 0.010 |
Why?
|
| Life Style | 1 | 2003 | 329 | 0.010 |
Why?
|
Concepts
(263)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(28)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People who are also in this person's primary department.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_
-->